Valuation: Diamyd Medical AB

Market Cap 159M 15.84M 14.16M 13.21M 12M 22.59M 1.53B 22.76M 62M 779M 59.48M 58.19M 2.51B P/E 2024
-10.2x
P/E 2025 -7.49x
Enterprise Value -118M -11.83M -10.57M -9.86M -8.96M -16.87M -1.14B -16.99M -46.29M -582M -44.4M -43.44M -1.87B EV / Sales 2024
11,578x
EV / Sales 2025 9,820x
Free-Float
83.81%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Diamyd Medical AB

1 day-5.80%
1 week-8.54%
Current month-8.54%
1 month-8.90%
3 months-15.89%
6 months-38.43%
Current year-91.63%
1 week 0.92
Extreme 0.924
1.05
1 month 0.92
Extreme 0.924
1.4
Current year 0.9
Extreme 0.896
17.88
1 year 0.9
Extreme 0.896
17.88
3 years 0.9
Extreme 0.896
25
5 years 0.9
Extreme 0.896
25.94
10 years 0.9
Extreme 0.896
74.7
Manager TitleAgeSince
Chief Executive Officer 85 2026-04-23
Director of Finance/CFO 53 2026-06-30
Chief Tech/Sci/R&D Officer 46 2012-12-31
Director TitleAgeSince
Chairman 85 2023-10-01
Director/Board Member 56 2008-12-31
Chairman 65 2026-04-23
Date Insider Type Main position Quantity % Market Cap. Importance
6/27/25 Don

Chief Executive Officer

100,000 0.0791%
5/5/25 Buy

Chief Executive Officer

1,000 0.0008%
5/2/25 Buy 1,020 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
-5.80%-8.54%-91.50%-88.11% 15.53M
+4.16%+4.16%+49.37%+94.17% 74.69B
+0.46%-0.97%+23.51%+79.34% 58.81B
+0.17%+0.35%+6.85%+34.55% 48.45B
+0.50%-2.14%+331.33%+702.20% 42.84B
-0.72%-3.99%+28.50%+29.94% 42.79B
+0.34%-0.52%+6.56%+109.35% 41.25B
-0.11%+1.96%+9.19%+52.66% 31.13B
-0.50%-3.10%-10.19%-14.35% 24.05B
-3.32%-10.86%-37.32%+316.28% 22.98B
Average -0.48%-2.33%+31.63%+131.60% 38.7B
Weighted average by Cap. +0.67%-1.80%+52.37%+149.37%

Financials

2024 2025
Net sales 130K 12.98K 11.6K 10.82K 9.83K 18.51K 1.26M 18.64K 50.79K 638K 48.72K 47.67K 2.05M 130K 12.98K 11.6K 10.82K 9.83K 18.51K 1.26M 18.64K 50.79K 638K 48.72K 47.67K 2.05M
Net income -152M -15.16M -13.54M -12.64M -11.48M -21.62M -1.47B -21.78M -59.32M -746M -56.91M -55.68M -2.4B -170M -16.95M -15.14M -14.13M -12.83M -24.17M -1.64B -24.35M -66.33M -834M -63.63M -62.25M -2.68B
Net Debt -132M -13.21M -11.81M -11.02M -10.01M -18.84M -1.28B -18.98M -51.71M -650M -49.61M -48.53M -2.09B -277M -27.67M -24.72M -23.07M -20.95M -39.46M -2.68B -39.75M -108M -1.36B -104M -102M -4.38B
Projected Income Statement - Annual - Diamyd Medical AB
Logo Diamyd Medical AB
Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.
Employees
44
Date Price Change Volume
26-10-07 SEK 0.9420 -5.80% 1,534,805
26-10-06 SEK 1.000 0.00% 1,088,734
26-10-05 SEK 1.000 -1.57% 1,102,206
26-10-02 SEK 1.016 -0.59% 243,214
26-10-01 SEK 1.022 -0.78% 436,731

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Diamyd Medical AB
  1. Stock Market
  2. Stocks
  3. DMYD B Stock